MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
Line 53: | Line 53: | ||
*The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | *The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor. | ||
*'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | *'''Dabrafenib''' ''e.g.'' [[4xv2]] - B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib. | ||
- | + | *B-Raf Kinase Inhibitor Zelboraf - Generic: '''Vemurafenib''' (Formerly: PLX-4032), see [[B-RAF with PLX4032]]. | |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 12:11, 21 February 2022
|
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089